Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | GSR | P00390 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fotemustine SCHEMBL16174560 | 0.88 | ALDH1A1 (0.44) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Fotemustine SCHEMBL8880 | 0.88 | ALDH1A1 (0.44) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Fotemustine SCHEMBL8881 | 0.88 | ALDH1A1 (0.44) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Fotemustine SCHEMBL7206688 | 0.87 | ALDH1A1 (0.43) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Fotemustine SCHEMBL3982212 | 0.85 | ALDH1A1 (0.42) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Lomustine SCHEMBL868328 | 0.79 | ADRA2A (1.00) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Lomustine SCHEMBL3995 | 0.79 | ADRA2A (1.00) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Fotemustine SCHEMBL14697056 | 0.79 | ALDH1A1 (0.36) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| SCHEMBL17524418 | 0.78 | GAA (0.36) | ALDH1A1SMN1; SMN2TSHRKMT2AMEN1 | |
| Lomustine SCHEMBL28262197 | 0.77 | ADRA2A (0.94) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174611-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| WO-2024028808-A1 | AROMATIC COMPOUNDS FOR USE AS PROTEIN PHOSPHATASE 2A (PP2A) MODULATORS | RAPPTA THERAPEUTICS OY (FI) | 2024-02-08 | — | — | WO | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| EP-4288414-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| CN-116806217-A | Substituted cyclic modulators of protein phosphatase 2A (PP 2A) and methods of use thereof | 拉帕塔疗法公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20230020161-A1 | Tricyclic Modulators of PP2A | RAPPTA THERAPEUTICS OY (FI) | 2023-01-19 | — | — | US | disclosed |
| EP-4110762-A1 | TRICYCLIC MODULATORS OF PP2A | Rappta Therapeutics Oy (FI) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022167867-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
| US-20210137910-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-05-13 | — | — | US | disclosed |
| EP-2888255-A2 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Board of Regents, The University of Texas System (US) | 2015-07-01 | — | — | EP | disclosed |
| US-9018380-B2 | Heterocyclic modulators of HIF activity for treatment of disease | Boar of Regents, The University of Texas System (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140073634-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140066424-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140057914-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2014031936-A2 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | JONES PHILIP (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031928-A2 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | JONES PHILIP (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031933-A2 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | JONES PHILIP (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2131840-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*Bio Pte Ltd (SG) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008108741-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*BIO PTE LTD (SG) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057914-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | ADRA2A 3382/4885PDE4A 1637/4885ADRA1A 3860/4885 |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | ADRA2A 521/4885PDE4A 192/4885ADRA1A 960/4885 |
| US-20230020161-A1 | Tricyclic Modulators of PP2A | PPP2CA, PPP4C, PPP3R1 | ADRA2A 1697/4885PDE4A 325/4885ADRA1A 1764/4885 |
| US-20140066424-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | ADRA2A 3382/4885PDE4A 1637/4885ADRA1A 3860/4885 |
| US-20240174611-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPP2CA, PPP3CA, PPP4C | ADRA2A 369/4885PDE4A 81/4885ADRA1A 982/4885 |
| US-20210137910-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, VHL, HIF1A | ADRA2A 3486/4885PDE4A 2211/4885ADRA1A 4055/4885 |
| US-20140073634-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | ADRA2A 3382/4885PDE4A 1637/4885ADRA1A 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.